Submitted to Magnetic Resonance in Medicine

Test-retest reproducibility of human brain multi-slice ¹H FID-MRSI data at 9.4 T after optimization of lipid regularization, macromolecular model and spline baseline stiffness

Author: Theresia Ziegs^{1,2,*}, Andrew Martin Wright^{1,2,*}, and Anke Henning^{1,3}

¹High-Field MR Center, Max Planck Institute for Biological Cybernetics, Tübingen, Germany

²IMPRS for Cognitive and Systems Neuroscience, Tübingen, Germany.

³Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas

* TZ and AMW contribute equally to this work.

Correspondence to: Theresia Ziegs, Max Planck Institute of Biological Cybernetics, Max-Planck-Ring 11, 72076 Tübingen, Germany; theresia.ziegs@tuebingen.mpg.de

Total Words: 4903

Key words: magnetic resonance imaging; human brain; lipid regularization; ultra-high field strengths; whole-brain mrsi

Supporting Information shall be used for review and online publication.

Abstract:

- **Purpose:** This study analyzes the effects of retrospective lipid suppression, a simulated macromolecular prior knowledge and different spline baseline stiffness values on 9.4 T multi-slice proton FID-MRSI data spanning the whole cerebrum of human brain and its reproducibility of metabolite ratio (/tCr) maps for 10 brain metabolites.
- **Methods:** Measurements were performed twice on five volunteers using a non-accelerated FID MRSI 2D sequence at 9.4 T. The effects of retrospective lipid L2-regularization, macromolecular spectrum and different LCModel baseline flexibilities on SNR, FWHM, fitting residual, CRLB and the concentration ratio maps were investigated. Intra-subject, inter-session coefficient of variation of the mean metabolite ratios (/tCr) of each slice was calculated.
- **Results:** L2-regularization provided effective suppression of lipid-artifacts, but should be avoided if no artifacts are detected. Transversal, sagittal and coronal of many metabolite ratio maps correspond to anatomically expected concentration relations in gray and white matter for the majority of the cerebrum when using a flexible baseline in LCModel fit. Additionally, results from the second measurements of the same subjects show that slice positioning and data quality correlate significantly to the first measurement.
- **Conclusion:** Concentration ratio maps (/tCr) for 4 metabolites (tCho, NAA, Glc, ml) spanning the majority and six metabolites (NAAG, GABA, GSH, Tau, Gln, Asp) covering 32 mm in the upper part of the brain were acquired at 9.4 T using multi-slice FID MRSI with retrospective lipid suppression, a macromolecular spectrum and a flexible LCModel baseline.

1. Introduction

Metabolite mapping with ^1H MRSI spanning a major part of the brain provides a comprehensive insight into the distribution of metabolites across different regions in the human brain. Thus, it is a valuable tool to obtain complimentary information to MRI, diffusion or fMRI techniques regarding brain metabolism¹, and has been used to examine for various diseases^{2–10}.

Most whole-brain ^1H MRSI studies have been conducted at field strengths $\leq 3\text{T}$ ^{11–26} showing concentration or ratio maps of maximal five metabolites NAA, Cr, Cho, mI and Glx. However, a study from Motyka et al.²⁷ compared whole-brain simulations of MRSI data for different field strengths from 1.5T, 3T, 7T up to 9.4T and concluded that MRSI benefits significantly from ultra-high field strengths in terms of SNR and spectral resolution. Ultra-high fields enable the detection of low concentrated metabolites such as N-acetylaspartylglutamate (NAAG), and the distinction between metabolites that are overlapped at lower field strengths ($< 3\text{T}$) such as glutamate (Glu) and glutamine (Gln).

While the majority of ultra-high field ^1H MRSI studies cover only a single slice^{28–35}, there are only very few ^1H MRSI investigations at ultra-high field strengths that show an extended coverage of the human brain^{36–41}. These publications were all using acceleration techniques and showing maps of a maximum of six metabolites (tCr, tNAA/NAA, tCho, Glu, Gln, mI) for a brain volume of a maximum of 110 mm and only one paper showed NAAG for a relatively small volume of 50 mm thickness³⁹. None of these ultra-high field ^1H MRSI studies investigated the intra-subject test-retest reproducibility, only one ultra-high field MRSI study investigated inter-subject reproducibility³⁷. In fact there is only one 2D ^1H MRSI study at 7T that presents intra-subject test-retest data from a single slice above the corpus callosum for tNAA, tCho, tCr, mI and Glx⁴².

In this paper, the number of metabolites quantified by ^1H MRSI from the human brain shall be extended and concentration ratio (/tCr) maps for 10 brain metabolites will be obtained, namely for NAA, tCho, Glu, and mI for the whole cerebrum and Gln, γ -aminobutyric acid (GABA), glutathione (GSH), NAAG, taurine (Tau) and aspartate (Asp) for a stack of FID-MRSI slices covering 32 mm in the upper part of the human brain. In addition, a test-retest analysis verified inter-session, intra-subject reproducibility of the multi-slice ^1H FID MRSI measurements of these

brain metabolites. For this purpose, the post-processing steps were systematically optimized and validated with optional lipid removal and macromolecular (MM) spectrum included in the fitting routine. Since these both influence the data's baseline, the impact of the spline baseline flexibility was investigated, which has not been done before for ^1H MRSI data, although accurate quantification rely strongly on baseline estimations^{43,44}.

2. Methods

2.1. Data Acquisition

2.1.1 Hardware

All measurements were performed using a 9.4T Magnetom whole-body MR scanner (Siemens Healthineers, Erlangen, Germany) using an in-house built radiofrequency (RF) array coil with 18 transmit and 32 receive channels⁴⁵. The receive channels consist of 18 transceiver surface loops and 14 receive only vertical loops in a double-row design.

2.1.2 Study-design

Five healthy volunteers (4 male and 1 female, aged 28 ± 2 years) provided written informed consent according to the local ethics board regulations and were scanned twice each.

Repositioning of each subject was carefully carried out by using the same padding under the head and neck and at the sides inside the tight fit RF coil housing for each measurement.

Planning of the MRSI slice position was aided by visual comparison of anatomical markers based on a sagittal 2D FLASH sequence which was acquired before each of the two ^1H MRSI scans.

2.1.3 Scan Protocol

Ten ^1H MRSI slices were acquired in all acquisitions. The total FOV ($220 \times 220 \times 80 \text{ mm}^3$) was divided into three blocks of individual transversal slices ($220 \times 220 \times 8 \text{ mm}^3$): the top and middle blocks both contained four slices each, and the bottom block contained only two slices. Figure 1a shows the positioning of the three blocks. The uppermost block was placed immediately above

the corpus callosum, and the two blocks below were positioned to extend the FOV based on the top block position.

Each block was B0 shimmed separately using the vendor implemented image-based second-order B0 shimming routine and a shim volume that extends an additional 4 mm beyond the bottom and top of each block of MRSI slices. The spectral data was circularly sampled using a 2D FID-MRSI sequence^{31,33,46} with a numerically optimized 3-pulse water-suppression scheme²⁹, but without any lipid or outer volume suppression. MRSI slices were acquired with a matrix size of 48×48 (nominal voxel size: 4.6×4.6×8mm³=170μL), TR=300ms, TE*=1.5ms, flip angle=48°, spectral width=8000Hz including oversampling, acquisition time=128 ms. After MRSI data acquisitions for each block, a non-water suppressed reference scan was acquired with the same parameters as the MRSI scan, but using a highly accelerated compressed sensing scheme with an acceleration factor of R~18^{28,47,48} to meet the scan time restrictions given by the local ethical committee. Additionally, a 2D FLASH scout image was acquired with TR=300ms, TE=6.1 ms, flip angle=25°, base resolution: 128x128 for the SENSE x-t sparse compressed sensing (CS) reconstruction of the water reference^{28,47,48}. The scan time for the water suppressed MRSI data, the water reference MRSI data, and scout image accumulated to 10 min per slice. The total scan time summed up to 2h including slice positioning and shimming.

2.2 Data Processing and Postprocessing

An overview of the different reconstruction steps is shown in Table 1 and steps 1 to 7 are described in more detail in the supplementary material.

The following sections explain the detail about the post-processing steps and the LCModel fitting procedure.

2.2.1 Lipid suppression by L2-regularization

Following the post-processing, the data stayed either as it is (“*non-regularized*”/“*nonreg*”) before spectral fitting or a retrospective lipid suppression method via L2-regularization (“*L2-regularized*”/“*L2*”) using an adaptation of Bilgic’s code⁴⁹ ($\beta=5000$, obtained from L-curves⁵⁰) was applied to reduce lipid contamination. Detailed information about the choice of the

regularization parameter β can be found in the Supplementary Material and in Supplementary Figure A.

2.2.2 Spectral fitting

The reconstructed MRSI data was fitted using LCModel (V6.3-1L)⁵¹ with a basis set simulated with VeSPA (version 0.9.5 <https://scion.duhs.duke.edu/vespa/>⁵²) consisting of 13 metabolites: Asp, tCr, GABA, Gln, Glu, glycine (Gly), GSH, mI, NAA, NAAG, scyllo-inositol (scyllo), Tau, tCho (glycerophosphocholine + phosphorylcholine). J-coupling constants and chemical shifts were taken from Govindaraju et al.^{53,54} except for GABA for which Near's values were used⁵⁵. The LCModel parameter dkntmn (minimum spacing of the spline baseline knots in ppm, cannot exceed one third of the fitted range⁵⁶) reflecting the spline baseline stiffness was set to 0.15 (default; most flexible), 0.25 (intermediate flexibility) or 1 (stiff) for comparison. The parameters of the LCModel control file and LCModel's basis set are attached in the Supplementary Material. In addition, two sample spectra for a gray matter (GM) rich and a white matter (WM) rich voxel with all fitted metabolites are shown in the Supplementary Figure B.

The short TR times used in this work led to strong T1-weighting of metabolites and macromolecules (MM). To account for MM contributions, a simulated MM spectrum (MM_{AXIOM} in Wright et al.⁵⁷) was used as part of the spectral basis set. This model considered T1- and T2-relaxation times of MM at 9.4T^{58,59} and took into consideration the TR and TE of the 1H MRSI sequence. LCModel's internal simulated MM or lipids were not included in the fitting. The relaxation corrected MM simulation model was used herein because it is not possible to acquire matching experimental macromolecular spectra with the same short TR and hence same T1 weighting as in the ¹H MRSI measurements due to the need of a dual inversion recovery module⁶⁰. Data fitted with the MM spectrum was compared to that without MM.

The following different configurations were compared: non-regularized data fitted without MM spectrum with dkntmn of 0.15, 0.25 and 1 (designated as *nonreg-0.15*, *nonreg-0.25* and *nonreg-1*, respectively), non-regularized data fitted with the simulated MM basis spectrum (designated as *nonreg-MM-0.15*, *nonreg-MM-0.25* and *nonreg-MM-1*, respectively), and L2-regularized data

fitted with the MM basis spectrum (designated as *L2-MM-0.15*, *L2-MM-0.25* and *L2-MM-1*, respectively).

2.3 Quality Measures & Test-Retest reliability

Different quality measures were used to compare the mentioned configurations and choose the best one as input for the subsequent test-retest analysis.

The contribution of skull lipid signal to the metabolite spectrum can elevate apparent metabolite peak amplitudes while a wrong adjustment of the regularization parameter in the retrospective lipid removal step can also suppress metabolite signal. To quantify this impact, the signal-to-noise ratio (SNR) of NAA and tCr were observed. Thus, the SNR of NAA and tCr were calculated as the ratio of the maximum peak of their methyl groups at 2 or 3 ppm derived from the LCModel fit to the root-mean-square (rms) of the noise region of the non-back-predicted ¹H FID MRSI data (to avoid baseline distortions caused by the back-prediction). In addition, a 2nd order polynomial fit of the baseline was subtracted prior to the noise level estimation. Using the maximum of the fitted metabolite spectra as the signal intensity allowed to account for baseline compensations from LCModel and the choice of different LCModel baseline stiffness'.

Furthermore, the full width half maximum (FWHM) linewidth of tCr as reported from LCModel, the root-mean-square (rms) of the fit residual and the Cramér-Rao lower bound (CRLB) as reported from LCModel were reported for all configurations. In addition, the brain coverage of different metabolites by using the percentage of voxels fitted with a CRLB < 40 % to compare it to previous published data³⁸, is shown.

To investigate the intra-subject reliability of the two measurements the coefficient of variance (CV), defined as standard deviation of the difference between measurements divided by the mean values from the measurements¹¹, were calculated for NAA/tCr, tCho/tCr, Glu/tCr, and mI/tCr with the mean concentration of each slice and for NAAG/tCr, GABA/tCr, GSH/tCr, Tau/tCr, Gln/tCr, Asp/tCr for slice 6-9 due to the insufficient quality in lower slices.

Two-sample t -tests with non-equal variances were used to prove statistical significance at the 5% significance level of the above mentioned quality measures for different configurations. Whenever changes are described as significant, this two-sample t -test was applied.

3. Results

3.1. Lipid Suppression

The lipid rms maps of non-regularized data show strong lipid contamination especially in slices 5 and 6, see Figure 1c. The impact of the regularizations on the spectra is shown in Figure 1b for strong and intermediate contaminated regions.

3.2 Signal-to-Noise-Ratio

Boxplots of the SNR of NAA and tCr for each configuration are displayed in Figure 2a+b. This reveals that the regularization influences different spectral ranges with varying effects: While the SNR of NAA decreases slightly after the regularization, the SNR of tCr changes less. These changes are statistically significant for all slices combined as well as for the single slices. A non-regularized configuration and a L2-regularized configuration are selected to illustrate the changes in different slices (Figure 2c+d): The SNR increases for slices 1 to slice 5, show decreased values for slice 6 and show highest values for slice 7 and 8.

3.3 Fitting Parameters

The FWHM as well as the rms of the fit residual increase with increasing $dkntmn$ as it is seen in Figure 2e and 2f, respectively. The FWHM changes significantly. The rms fit residual are slightly smaller for all L2-regularized cases than for the non-regularized configurations. These changes are statistically significant, while the rms fit residual for non-regularized data does not change significantly for the data with and without MM spectrum for the same $dkntmn$ value. The fit residual can be seen in the Supplementary Figure C for one sample voxel for all configurations.

The CRLB increases with increasing $dkntmn$ value for all shown metabolites, see Figure 3a and Supplementary Figure D. The same behavior is seen in the voxels fitted in $CRLB < 40\%$, see Figure 3b.

3.4 Qualitative Analysis

In Figure 4, metabolite ratio maps are shown for selected slices for Glu/tCr (a), NAA/tCr (b), NAAG/tCr (c) for all configurations to illustrate the effects of different dkntmn values, MM spectra and lipid regularization. tCr ratios were used to include B_1^+ and B_1^- correction³¹. In Figure 5, metabolite ratio maps for the sagittal and coronal slices (a) for NAA/tCr, tCho/tCr, Glu/tCr and mI/tCr is shown as well as all measured transversal slices (b) for one volunteer for 10 different metabolites of the configuration *L2-MM-0.25*.

3.5 Test-retest Analysis

In Figure 6, test-retest ratio maps are shown for all 10 metabolites of the configuration *L2-MM-0.25*. In Table 2, the CV for the same metabolites were summarized, the corresponding boxplots including 25- and 75 % percentile can be found in the Supplementary Figure E.

4. Discussion

In the present study, non-accelerated multi-slice FID-MRSI data encompassing the cerebrum of five volunteers were acquired and analyzed with regard to the effects of an included MM spectrum and different values of the LCModel stiffness parameter in the fitting routine on non-regularized and lipid-regularized data. In addition, a second measurement on the same volunteer were performed and the effects of the mentioned configurations on intra-subject reliability were investigated.

In the next subsections, the calculated quality measures will be discussed with respect to the MM spectrum used in the fit, the influence of the retrospective lipid suppression and the choice of LCModel's baseline flexibility. Finally, the metabolic ratio maps and the test-retest results will be discussed.

4.1 Influence of the MM spectrum

The correct estimation of the macromolecular signal is crucial for the accurate determination of metabolite concentration⁶⁰. Several ultra-high field studies presented a measured full MM spectrum or decomposed MM signal into individual components for SVS^{44,56,61} as well as for

MRSI data^{42,62,63}. A simulated model is favorable in cases of limited scan time and when experimental acquired MM spectra cannot be obtained as it is the case in the present study. The present MM-model was successfully tested before on SVS data on 9.4 T⁵⁷ for STEAM and semi-LASER, but is adaptable to different sequences, so also to FID-MRSI. In addition, it could also be adapted for different tissue types, but the impact was found to be minor⁶⁴ and the experts' consensus was that a constant shape of the MM can be a practical approach⁶⁰. To observe the influence of the MM model on the present data, the non-regularized data fitted with and without a simulated MM spectrum (*nonreg* vs *nonreg-MM*) will be compared. The SNR of NAA and tCr is higher for *nonreg* configurations without the MM spectrum than with the MM spectrum for all dkntmn values, since MM peaks overlap with the peaks of NAA and tCr at 2 and 3 ppm, respectively. Thus, the fitted concentrations are reduced when using a MM baseline, which does not imply that the data quality is worse. The other quality measures (FWHM, the rms fit residual and the CRLB for tCho, NAA, tCr and Glu) did not differ significantly. Only the CRLB for mI was significantly higher when fitted with the MM spectrum which is caused since the MM spectrum and mI have both peaks around 3.5 ppm. The peaks are assigned completely to mI if no MM basis spectrum is used and to both if a MM basis spectrum is included which decreases the mI concentration and elevated the CRLB for mI. The ratio maps of mI/tCr do not show a quantitative improvement when including or not including the MM spectrum, see Supplementary Figure F.

Since these measures do not answer the question if the MM spectrum should be used or not, metabolite ratio maps were investigated qualitatively. A dominant impact of the MM spectrum was visually observed for NAAG/tCr, see Figure 4c. NAAG is expected to be much higher in the WM^{33,63,65} and the maps obtained in this study for dkntmn < 1 look much more similar to what has been published before⁶⁴ when including the MM spectrum in the fit than without.

Consequently, it could be shown that the simulated MM-model could successfully be applied to FID-MRSI data, but in a final decision step, its impact on quantitative metabolic concentrations should be investigated, which is beyond the scope of this study.

4.2 Retrospective Lipid Suppression

Although, lipid suppression by L2 is widely used, there are only few publications beside the original article by Bilgic et al.⁴⁹ (one paper combining water and lipid removal by Lin et al.⁶⁶ and an abstract from Hangel et al.⁶⁷) investigating the lipid removal by L2-regularization in more detail. All other MRSI publications at ultra-high fields using L2 (or rarely L1) give no hints on how they found the optimal regularization parameter and rarely report the value at all. Thus, it is essential to analyze the impact of L2 in more detail by comparing non-regularized data to L2-regularized data (*nonreg-MM* vs *L2-MM*).

On one hand, the lipid contamination can be efficacious reduced when using L2-regularization, see third row of Figure 1; however, on the other hand, it also strongly reduces the NAA CH₃ peak height as seen in the sample spectra of Figure 1b. This can be partly traced back to a baseline distortion caused by the lipid regularization and partly to a peak reduction of peaks close to the chemical shift of the lipids (0.9 – 1.3 ppm), which results in stronger reduction of the SNR of NAA than the SNR of Cr, although both changes were statistically significant. The quality measures of the fitted data show no clear trend: The CRLB is partly significantly lower or higher and partly non-significantly different depending on the metabolite and the *dkntmn* value chosen; but the FWHM and the fit residual is significantly lower for all lipid-regularized cases and the number of voxels fitted with CRLB < 40 % is higher for most metabolites. Overall, the range of the median values for voxels fitted with CRLB < 40 % was calculated for the whole volume for tCr: 88-90 %, tCho: 90-93 %, Glu: 86-91 %, mI: 76-89 % and NAA: 88-98 % for the configurations *nonreg-MM* and *L2-MM* with *dkntmn* = 0.15 and 0.25. Higher *dkntmn* values lead to lower % of voxels fitted and were not reported here. These values are similar to the values reported from Hingerl et al.³⁸ in a 3D-MRSI study from the highest quality region: tCr: 91 %, tCho: 93%, Glu: 91%, mI: 92 %, and tNAA: 94%.

To decide finally whether to use the lipid suppression or not, the NAA/tCr and Glu/tCr maps will be inspected, since they show the strongest effects of lipid suppression of all investigated metabolites, see Figure 4a+b. It turns out that lipid suppressed data reduces the artifacts clearly, which are present in the non-regularized data (no matter which *dkntmn* values was used). Especially the artifacts in slice 5 were reduced (for both metabolites), but also the data loss in slice 6 in the Glu/tCr maps could be removed and the increase of the NAA/tCr concentration in

peripheral voxels in slice 6 and peripheral artifacts in slice 7 for both metabolites cannot be detected in the L2-regularized data. Hence, while L2-regularization reduces artifacts effectively, it does not create new artifacts as it can be seen for all other slices for NAA/tCr and Glu/tCr in Supplementary Figure G.

4.3 Spline Baseline Flexibility

No previous literature systematically analyzed the influence of different LCModel's `dkntmn` values on metabolite maps. Most papers do even not report the used `dkntmn` value. There is one study on baseline problems using a different fitting tool for SVS and MRSI data⁴³ showing that baseline-fitting errors can be drawn back to too stiff and too flexible baselines leading to underfitting and overfitting, respectively. Since LCModel is most widely used, it is crucial to systematically investigate its internal spline baseline flexibility.

There are several SVS studies which are comparing different `dkntmn` values, but those results should only be adapted with caution since the baseline distortion is stronger for MRSI than for SVS data. Previous studies on human SVS data show that LCModel's default baseline stiffness (0.15) may be too flexible and encourage stiffer baselines^{56,61,68,69} to avoid quantification errors due to fitting ambiguity, but no conclusion on a best value was drawn. A SVS study in rat brain from Simicic et al⁷⁰ concluded that a `dkntmn` value < 1 is preferred when comparing the concentrations to a ground truth. But no generally valid value for `dkntmn` was predicted since it is i.a. depending on the MM spectrum used.

For the MRSI data in the present study, it can also be concluded that a very stiff baseline (`dkntmn`=1) is not a good choice: The SNR values are lowest, the FWHM highest, the rms of the fit residual increased and the CRLB are highest and the number of voxels fitted thus lowest. The NAAG maps show obviously anatomically incorrect results. Although the LCModel's default baseline stiffness (`dkntmn`=0.15) show in most cases better values of the quality metrics' than a `dkntmn` value of 0.25, it has to be kept in mind that an overflexible baseline potentially leads to quantification errors⁶¹. Further investigations including the comparison of quantitative metabolite concentrations for different `dkntmn` values should be carried out to find an optimal baseline

stiffness. But a $dkntmn$ value close 0.25 is potentially a preferred choice for MRSI data. In MRSI papers values of 0.15⁴² and 0.3⁷¹ were found.

4.4 Metabolite Ratio Maps

In the previous subsection, it has been shown that L2-regularized data fitted with a flexible baseline and a MM prior knowledge is the best choice. Thus, the configuration *L2-MM-0.25* was chosen for presenting metabolite ratio maps in Figure 5. Since no tissue segmentation was done in this study, the concentration ratio maps can only visually be compared to previous literature, but correspond mostly well to the expected ratios of GM and WM: higher concentration in WM than GM for $tCho/tCr$ ^{21,37–40,46}, mI/tCr ^{39,46}, $NAAG/tCr$ ^{31,39,63,65} and higher concentrations in GM for Glu/tCr ^{31,37,38,40,46}, $GABA/tCr$ ^{31,72,73}, Gln/tCr ^{31,74}, Tau/tCr ^{31,74}, Asp/tCr ³¹. For some metabolites even more anatomical details are seen in the maps which correspond to the literature: NAA/tCr is higher in the corpus callosum and thalamus³⁷; $tCho/tCr$ is concentrated higher in the frontal cortex than in the occipital lobe^{21,38–40} and strongly in corpus callosum and thalamus³⁷. In the literature NAA/tCr is higher in WM than GM^{21,31,39,46,63}, while the transversal concentration ratio maps in Figure 5b show a rather evenly distributed NAA/tCr concentration and look similar to the maps presented in other publications^{12,31}. Also the values for GSH/tCr were difficult to compare: Previous literature show higher GSH concentration in GM⁷⁵, but for the concentration ratio, literature results are not consistent: GSH/tCr is found to be similar in GM and WM⁷¹, higher or lower in GM depending on the resolution³¹ or slightly higher in WM than in GM³⁷, but our values are definitely higher in WM. A possible reason could large signals from other metabolites overlap with GSH which hampers its fitting^{76,77}.

Overall: the best results were achieved in the upper slices (slice 6-9, corresponds to a slab of 32 mm thickness) for all volunteers, which can be easily understood since the shim is best in this region: the FWHM is smallest, see Figure 2g, and SNR is biggest, see Figure 2c+d. In this volume $tCho$, NAA , Glu , mI , Gln , $GABA$, GSH , Tau , Asp and $NAAG$ show good quality metabolite ratio ($/tCr$) maps. Slice 10 covered only a very limited number of brain voxels and thus, the data of the top slice was strongly contaminated by the surrounding lipid from the skull. No information could be obtained for this slice for any volunteer. The slices of the lowest block (slice 1 and 2) suffer from static magnetic field (B_0) inhomogeneity caused by the nasal sinus in

the frontal region. Depending on the volunteer's head size, shape and relative orientation to the outer magnetic field information of only a few metabolites (NAA, tCr, tCho, Glu and mI) could be achieved in these lower brain slices. Slices 3-5, too, suffer from the mentioned B_0 inhomogeneity and reasonable concentration ratio maps could be achieved for some volunteers for NAA, tCr, tCho, Glu and mI.

Overall, in some metabolite ratio maps other artifacts especially in slice 5 are still present after L2-regularization, which could either be caused by the higher peripheral and lower central receive sensitivity of overlapping coil elements (see Figure 1 in Avdievitch et al.⁴⁵). Other artifacts could be explained by motion during the long duration of the scan. Motion would have diminished the B_0 homogeneity achieved by the B_0 shimming procedure and thus reduced the quality of the MRSI data. In addition, motion in between the MRSI data and the water reference acquisition (time difference of 10-40 minutes), could have created mismatches between the slice position of the water suppressed and non-water suppressed data.

4.5 Inter-session, Intra-subject reliability

Although there are numerous test-retest studies of MRSI^{13,22,25,26,42,78,79} (and even more for SVS⁸⁰⁻⁹⁰) data, comparing their CVs to the present data is challenging since many do not show CVs of concentration ratios but of the absolute concentration and secondly, often voxelwise CVs are reported averaged from different brain regions or tissue types, while in the present study CVs were calculated slicewise. Nonetheless, the most comparable studies will be cited in the next paragraph beginning with (towards) whole-brain studies. Single-slice MRSI as well as SVS reproducibility CVs were only cited as a rough guide for the CVs of those metabolites, which are not reported in whole-brain studies.

In the present study the mean inter-session, intra-subject CV for the configurations *nonreg-MM* and *L2-MM* using dkntmn values of 0.15 or 0.25 ranges from 6.2-8.5 %, 4.6-5.1 %, 6.5-10.3 % and 7.4-16.7 %, for NAA/tCr, tCho/tCr, Glu/tCr and mI/tCr for the whole volume, respectively. And the CVs for slice 6-9 were found to be 15.0-17.3 %, 8.2-13.8 %, 16.1-22.3 %, 19.5-33.7 %, 18.8-35.3 %, 6.2-10.5 % for Asp/tCr, GABA/tCr, Gln/tCr, NAAG/tCr, Tau/tCr, GSH/tCr, respectively. To our best knowledge, there are no reproducibility studies at ultra-high fields

encompassing a larger volume in the brain. There are a few other studies reporting inter-session, intra-subject CVs at lower fields for concentration ratios (/tCr) of NAA, tCho, mI and Glx. Their values are similar to those reported here: Zhang et al.²⁶ calculated mean intra-subject CVs from 3 sessions in different regions from whole-brain EPSI data at 3T of NAA/tCr: 6%, tCho/tCr: 6.5 % and mI/tCr: 10.5 %. Maudsley et al.²² calculated mean intra-subject CVs from 5 session acquired with SE MRSI at 3T ranging from NAA/tCr: 1.8-11 % and tCho/tCr: 2.7-10.2 % for different regions and Gu et al.¹³ reported from 6 scans acquired with 3D MRSI ranging from NAA/tCr: 2.3-12.7 % and tCho/tCr: 2.0-7.1 % for different regions at 1.5 T. Hnilitova et al.⁷⁹ calculated CVs of Glx/tCr of 4-8% and GABA+macromolecules/tCr of 6-10% (minimal-maximal value of medians) for using MEGA-LASER 3D MRSI sequence at 3T. Others reported intra-session or inter-subject CV and will not be compared^{11,23,25,37}. Due to the lack of comparable high-field reproducibility studies with large volumes with more metabolites, the CVs of a single-slice study at 7T from Heckova et al.⁴² will be referenced. They showed voxel-by-voxel single-slice CVs for different brain regions of tNAA/tCr: 7 %, tCho/tCr: 5.9 %, mI/tCr: 7 %, Glx/tCr: 8.1 %, Glu/tCr: <12%, GSH/tCr: <15%, and Gln/tCr and Tau/tCr of <20%. These values are in a similar range as the present data with the CVs of mI/tCr and Tau/tCr being slightly smaller, and GSH/tCr being slightly higher than in our results. CVs for Asp and NAAG could not be found in other MRSI studies. In SVS studies values of mean CVs for NAAG/tCr for the posterior cingulate cortex of 24.8%⁸³ at 7T, which is in the middle of our CV values for different configurations. Reference CVs of Asp/tCr could not be found.

Except for tCho, the CV values show better results for nonregularized data than for L2-regularized data. It is thus concluded that as long as no lipid artifacts are visually seen, nonregularized data might be the better choice.

4.6. Limitations and future work

A recent review paper summarizes all previous publications about accelerated MRSI (> 200) and includes recommendations on which of them are applicable to 1H MRSI at ultra-high field⁹¹. A commonality between all previous ultra-high field “whole-brain” ¹H MRSI studies^{36–40} is that they used acceleration methods to achieve (towards) extended brain coverage in short scan times. In contrast, the aim of the current study was to use a non-accelerated approach to achieve high

spectral and spatial resolution metabolite maps for 10 brain metabolites that shall serve as a reference for neuroscientific and clinical studies and also as a ground truth for future analysis on the impact of different acceleration methods.

In future studies, the B0 shimming performance should be further improved to obtain better quality spectra in lower brain regions and to reduce remaining artifacts especially in the middle area of the measured volume (around slice 5). However, in spite of the investigation of different hardware and software solutions this is a problem so far not solved by the entire MRI developer community^{1,92}. In addition, the reduction of motion artifacts is needed by prospective motion correction as well to make whole brain 1H MRSI at ultra-high field more appropriate for clinical studies.

5. Conclusion

In this study, reproducible concentration ratio maps (/tCr) of tCho, NAA, Glu, and mI for the whole cerebrum and of NAAG, GABA, GSH, Tau, Gln, Asp for a volume of 32 mm thickness were obtained for five volunteers with good correspondence to the anatomical structure using fully sampled multi-slice 1H FID MRSI data at 9.4T with retrospective L2-lipid-regularization, an optimized flexible fitting baseline and a simulated-MM model.

Funding: SYNAPLAST (Grant No. 679927 to T.Z., A.M.W., and A.H.) and Cancer Prevention and Research Institute of Texas (CPRIT) (Grant No. RR180056 to A.H.)

References

1. Maudsley AA, Andronesi OC, Barker PB, et al. Advanced magnetic resonance spectroscopic neuroimaging: Experts' consensus recommendations. *NMR Biomed.* April 2020:e4309. doi:10.1002/nbm.4309
2. Roy B, Gupta RK, Maudsley AA, et al. Utility of multiparametric 3-T MRI for glioma characterization. *Neuroradiology.* 2013;55(5):603-613. doi:10.1007/s00234-013-1145-x
3. Maudsley AA, Gupta RK, Stoyanova R, et al. Mapping of Glycine Distributions in Gliomas. *Am J Neuroradiol.* 2014;35(Supplement 6):S31-S36. doi:10.3174/ajnr.A3845
4. Mueller C, Lin JC, Thannickal HH, et al. No evidence of abnormal metabolic or inflammatory activity in the brains of patients with rheumatoid arthritis: results from a preliminary study using whole-brain magnetic resonance spectroscopic imaging (MRSI). *Clin Rheumatol.* 2020;39(6):1765-1774. doi:10.1007/s10067-019-04923-5
5. Govind V, Sharma KR, Maudsley AA, Arheart KL, Saigal G, Sheriff S. Comprehensive Evaluation of Corticospinal Tract Metabolites in Amyotrophic Lateral Sclerosis Using Whole-Brain 1H MR Spectroscopy. Baron J-C, ed. *PLoS One.* 2012;7(4):e35607. doi:10.1371/journal.pone.0035607
6. Stagg CJ, Knight S, Talbot K, Jenkinson M, Maudsley AA, Turner MR. Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS. *Neurology.* 2013;80(7):610-615. doi:10.1212/WNL.0b013e318281ccec
7. Al-iedani O, Lechner-Scott J, Ribbons K, Ramadan S. Fast magnetic resonance spectroscopic imaging techniques in human brain- applications in multiple sclerosis. *J Biomed Sci.* 2017;24(1):17. doi:10.1186/s12929-017-0323-2
8. Maudsley AA, Govind V, Levin B, Saigal G, Harris L, Sheriff S. Distributions of Magnetic Resonance Diffusion and Spectroscopy Measures with Traumatic Brain Injury. *J Neurotrauma.* 2015;32(14):1056-1063. doi:10.1089/neu.2014.3505
9. Maudsley AA, Govind V, Saigal G, Gold SG, Harris L, Sheriff S. Longitudinal MR Spectroscopy Shows Altered Metabolism in Traumatic Brain Injury. *J Neuroimaging.* 2017;27(6):562-569. doi:10.1111/jon.12463
10. Öz G, Alger JR, Barker PB, et al. Clinical proton MR spectroscopy in central nervous system disorders. *Radiology.* 2014;270(3):658-679. doi:10.1148/radiol.13130531
11. Ding X-Q, Maudsley AA, Sabati M, Sheriff S, Dellani PR, Lanfermann H.

- Reproducibility and reliability of short-TE whole-brain MR spectroscopic imaging of human brain at 3T. *Magn Reson Med*. 2015;73(3):921-928. doi:10.1002/mrm.25208
12. Govind V, Gold S, Kaliannan K, et al. Whole-brain proton MR spectroscopic imaging of mild-to-moderate traumatic brain injury and correlation with neuropsychological deficits. *J Neurotrauma*. 2010;27(3):483-496. doi:10.1089/neu.2009.1159
13. Gu M, Kim DH, Mayer D, Sullivan E V., Pfefferbaum A, Spielman DM. Reproducibility study of whole-brain 1H spectroscopic imaging with automated quantification. *Magn Reson Med*. 2008;60(3):542-547. doi:10.1002/mrm.21713
14. Ebel A, Soher BJ, Maudsley AA. Assessment of 3D proton MR echo-planar spectroscopic imaging using automated spectral analysis. *Magn Reson Med*. 2001;46(6):1072-1078. doi:10.1002/mrm.1301
15. Posse S, Tedeschi G, Risinger R, Ogg R, Bihan D Le. High Speed 1H Spectroscopic Imaging in Human Brain by Echo Planar Spatial-Spectral Encoding. *Magn Reson Med*. 1995;33(1):34-40. doi:10.1002/mrm.1910330106
16. Esmaeili M, Bathen TF, Rosen BR, Andronesi OC. Three-dimensional MR spectroscopic imaging using adiabatic spin echo and hypergeometric dual-band suppression for metabolic mapping over the entire brain. *Magn Reson Med*. 2017;77(2):490-497. doi:10.1002/mrm.26115
17. Adalsteinsson E, Irrarrazabal P, Topp S, Meyer C, Macovski A, Spielman DM. Volumetric spectroscopic imaging with spiral-based k-space trajectories. *Magn Reson Med*. 1998;39(6):889-898. doi:10.1002/mrm.1910390606
18. Schirda C V., Zhao T, Yushmanov VE, et al. Fast 3D rosette spectroscopic imaging of neocortical abnormalities at 3 T: Assessment of spectral quality. *Magn Reson Med*. 2018;79(5):2470-2480. doi:10.1002/mrm.26901
19. Klauser A, Klauser P, Grouiller F, Courvoisier S, Lazeyras F. Whole-brain high-resolution metabolite mapping with 3D compressed-sensing SENSE low-rank 1H FID-MRSI. *NMR Biomed*. 2021;(August 2020):1-14. doi:10.1002/nbm.4615
20. Lecocq A, Le Fur Y, Maudsley AA, et al. Whole-brain quantitative mapping of metabolites using short echo three-dimensional proton MRSI. *J Magn Reson Imaging*. 2015;42(2):280-289. doi:10.1002/jmri.24809
21. Maudsley AA, Domenig C, Govind V, et al. Mapping of brain metabolite distributions by

- volumetric proton MR spectroscopic imaging (MRSI). *Magn Reson Med*. 2009;61(3):548-559. doi:10.1002/mrm.21875
22. Maudsley AA, Domenig C, Sherif S. Reproducibility of serial whole-brain MR Spectroscopic Imaging. *NMR Biomed*. 2010;23(3):n/a-n/a. doi:10.1002/nbm.1445
23. Moser P, Eckstein K, Hingerl L, et al. Intra-session and inter-subject variability of 3D-FID-MRSI using single-echo volumetric EPI navigators at 3T. *Magn Reson Med*. 2020;83(6):1920-1929. doi:10.1002/mrm.28076
24. Sabati M, Sherif S, Gu M, et al. Multivendor implementation and comparison of volumetric whole-brain echo-planar MR spectroscopic imaging. *Magn Reson Med*. 2015;74(5):1209-1220. doi:10.1002/mrm.25510
25. Veenith T V., Mada M, Carter E, et al. Comparison of inter subject variability and reproducibility of whole brain proton spectroscopy. *PLoS One*. 2014;9(12):1-23. doi:10.1371/journal.pone.0115304
26. Zhang Y, Taub E, Salibi N, et al. Comparison of reproducibility of single voxel spectroscopy and whole-brain magnetic resonance spectroscopy imaging at 3T. *NMR Biomed*. 2018;31(4):e3898. doi:10.1002/nbm.3898
27. Motyka S, Moser P, Hingerl L, et al. The influence of spatial resolution on the spectral quality and quantification accuracy of whole-brain MRSI at 1.5T, 3T, 7T, and 9.4T. *Magn Reson Med*. 2019;82(2):551-565. doi:10.1002/mrm.27746
28. Nassirpour S, Chang P, Avdievitch N, Henning A. Compressed sensing for high-resolution nonlipid suppressed 1 H FID MRSI of the human brain at 9.4T. *Magn Reson Med*. 2018;80(6):2311-2325. doi:10.1002/mrm.27225
29. Chang P, Nassirpour S, Avdievitch N, Henning A. Non-water-suppressed 1 H FID-MRSI at 3T and 9.4T. *Magn Reson Med*. 2018;80(2):442-451. doi:10.1002/mrm.27049
30. Nassirpour S, Chang P, Kirchner T, Henning A. Over-discretized SENSE reconstruction and B 0 correction for accelerated non-lipid-suppressed 1 H FID MRSI of the human brain at 9.4 T. *NMR Biomed*. 2018;31(12):e4014. doi:10.1002/nbm.4014
31. Nassirpour S, Chang P, Henning A. High and ultra-high resolution metabolite mapping of the human brain using 1 H FID MRSI at 9.4T. *Neuroimage*. 2018;168:211-221. doi:10.1016/j.neuroimage.2016.12.065
32. Nassirpour S, Chang P, Henning A. MultiNet PyGRAPPA: Multiple neural networks for

- reconstructing variable density GRAPPA (a 1H FID MRSI study). *Neuroimage*. 2018;183:336-345. doi:10.1016/j.neuroimage.2018.08.032
33. Henning A, Fuchs A, Murdoch JB, Boesiger P. Slice-selective FID acquisition, localized by outer volume suppression (FIDLOVS) for 1H-MRSI of the human brain at 7 T with minimal signal loss. *NMR Biomed*. 2009;22(7):683-696. doi:10.1002/nbm.1366
34. Kirchner T, Fillmer A, Tsao J, Pruessmann KP, Henning A. Reduction of voxel bleeding in highly accelerated parallel 1H MRSI by direct control of the spatial response function. *Magn Reson Med*. 2015;73(2):469-480. doi:10.1002/mrm.25185
35. Kirchner T, Fillmer A, Henning A. Mechanisms of SNR and line shape improvement by B0 correction in overdiscrete MRSI reconstruction. *Magn Reson Med*. 2017;77(1):44-56. doi:10.1002/mrm.26118
36. Esmaeili M, Strasser B, Bogner W, Moser P, Wang Z, Andronesi OC. Whole-Slab 3D MR Spectroscopic Imaging of the Human Brain With Spiral-Out-In Sampling at 7T. *J Magn Reson Imaging*. 2021;53(4):1237-1250. doi:10.1002/jmri.27437
37. Hangel G, Spurny-Dworak B, Lazen P, et al. Inter-subject stability and regional concentration estimates of 3D-FID-MRSI in the human brain at 7 T. *NMR Biomed*. 2021;(May):1-20. doi:10.1002/nbm.4596
38. Hingerl L, Strasser B, Moser P, et al. Clinical High-Resolution 3D-MR Spectroscopic Imaging of the Human Brain at 7 T. *Invest Radiol*. 2020;55(4):239-248. doi:10.1097/RLI.0000000000000626
39. Klauser A, Strasser B, Thapa B, Lazeyras F, Andronesi O. Achieving high-resolution 1H-MRSI of the human brain with compressed-sensing and low-rank reconstruction at 7 Tesla. *J Magn Reson*. 2021;331:107048. doi:10.1016/j.jmr.2021.107048
40. Moser P, Bogner W, Hingerl L, et al. Non-Cartesian GRAPPA and coil combination using interleaved calibration data – application to concentric-ring MRSI of the human brain at 7T. *Magn Reson Med*. 2019;82(5):1587-1603. doi:10.1002/mrm.27822
41. Nassirpour S, Chang P, Henning A. Whole Brain High Resolution Metabolite Mapping Using 1H FID MRSI with Slice-wise B0 Shim Updating at 9.4T. *Proc Jt Annu Meet ISMRM-ESMRMB, Paris, Fr*. 2018.
42. Heckova E, Považan M, Strasser B, et al. Effects of different macromolecular models on reproducibility of FID-MRSI at 7T. *Magn Reson Med*. 2020;83(1):12-21.

doi:10.1002/mrm.27922

43. Wilson M. Adaptive baseline fitting for 1H MR spectroscopy analysis. *Magn Reson Med*. 2021;85(1):13-29. doi:10.1002/mrm.28385
44. Giapitzakis I, Borbath T, Murali-Manohar S, Avdievich N, Henning A. Investigation of the influence of macromolecules and spline baseline in the fitting model of human brain spectra at 9.4T. *Magn Reson Med*. 2019;81(2):746-758. doi:10.1002/mrm.27467
45. Avdievich NI, Giapitzakis I-A, Bause J, Shajan G, Scheffler K, Henning A. Double-row 18-loop transceive-32-loop receive tight-fit array provides for whole-brain coverage, high transmit performance, and SNR improvement near the brain center at 9.4T. *Magn Reson Med*. 2019;81(5):3392-3405. doi:10.1002/mrm.27602
46. Bogner W, Gruber S, Trattnig S, Chmelik M. High-resolution mapping of human brain metabolites by free induction decay 1H MRSI at 7T. *NMR Biomed*. 2012;25(6):873-882. doi:10.1002/nbm.1805
47. Chang P, Nassirpour S, Henning A. Compressed sensing for 1H MRSI in the human brain at 9.4T. In: *ESMRMB*. ; 2017.
48. Chang P, Nassirpour S, Henning A. Highly Accelerated (R=14) Water Reference Acquisition for High Resolution 1H MRSI using Compressed Sensing. In: *Joint Annual Meeting ISMRM-ESMRMB 2018*. ; 2018.
49. Bilgic B, Chatnuntawech I, Fan AP, et al. Fast image reconstruction with L2-regularization. *J Magn Reson Imaging*. 2014;40(1):181-191. doi:10.1002/jmri.24365
50. Hansen PC. The L-Curve and its Use in the Numerical Treatment of Inverse Problems. *Comput Inverse Probl Electrodynamol*. 2000;4(4):119-142. doi:10.1.1.33.6040
51. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. *Magn Reson Med*. 1993;30(6):672-679. doi:10.1002/mrm.1910300604
52. Soher BJ, Semanchuk P, Todd D, Steinberg J, Young K. *VeSPA: Integrated Applications for RF Pulse Design, Spectral Simulation and MRS Data Analysis*.; 1994.
53. Govindaraju V, Young K, Maudsley AA, Karl Y, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. *NMR Biomed*. 2000;13(3):129-153. doi:10.1002/1099-1492(200005)13:3<129::AID-NBM619>3.0.CO;2-V
54. Govind V, Young K, Maudsley AA. Corrigendum: Proton NMR chemical shifts and coupling constants for brain metabolites. Govindaraju V, Young K, Maudsley AA, *NMR*

- Biomed* . 2000; 13: 129-153. *NMR Biomed*. 2015;28(7):923-924. doi:10.1002/nbm.3336
55. Near J, Evans CJ, Puts NAJ, Barker PB, Edden RAE. J -difference editing of gamma-aminobutyric acid (GABA): Simulated and experimental multiplet patterns. *Magn Reson Med*. 2013;70(5):1183-1191. doi:10.1002/mrm.24572
56. Marjańska M, Terpstra M. Influence of fitting approaches in LCModel on MRS quantification focusing on age-specific macromolecules and the spline baseline. *NMR Biomed*. 2019;34(5):1-9. doi:10.1002/nbm.4197
57. Wright AM, Murali-Manohar S, Borbath T, Avdievich NI, Henning A. Relaxation-corrected macromolecular model enables determination of 1 H longitudinal T 1 - relaxation times and concentrations of human brain metabolites at 9.4T. *Magn Reson Med*. 2022;87(1):33-49. doi:10.1002/mrm.28958
58. Murali-Manohar S, Wright AM, Borbath T, Avdievich NI, Henning A. A novel method to measure T1-relaxation times of macromolecules and quantification of the macromolecular resonances. *Magn Reson Med*. 2020;85(2):601-614. doi:10.1002/mrm.28484
59. Murali-Manohar S, Borbath T, Wright AM, Soher B, Mekle R, Henning A. T2 relaxation times of macromolecules and metabolites in the human brain at 9.4 T. *Magn Reson Med*. 2020;84(2):542-558. doi:10.1002/mrm.28174
60. Cudalbu C, Behar KL, Bhattacharyya PK, et al. Contribution of macromolecules to brain 1H MR spectra: Experts' consensus recommendations. *NMR Biomed*. 2021;34(5). doi:10.1002/nbm.4393
61. Giapitzakis I-A, Avdievich N, Henning A. Characterization of macromolecular baseline of human brain using metabolite cycled semi-LASER at 9.4T. *Magn Reson Med*. 2018;80(2):462-473. doi:10.1002/mrm.27070
62. Považan M, Strasser B, Hangel G, et al. Simultaneous mapping of metabolites and individual macromolecular components via ultra-short acquisition delay 1H MRSI in the brain at 7T. *Magn Reson Med*. 2018;79(3):1231-1240. doi:10.1002/mrm.26778
63. Považan M, Hangel G, Strasser B, et al. Mapping of brain macromolecules and their use for spectral processing of 1 H-MRSI data with an ultra-short acquisition delay at 7 T. *Neuroimage*. 2015;121:126-135. doi:10.1016/j.neuroimage.2015.07.042
64. Wright AM, Murali-Manohar S, Ziegs T, Henning A. Relaxation corrected simulated MM model for improved fitting and quantification of 1H FID MRSI data. In: *ISMRM*. ;

- 2021:2007. <https://index.mirasmart.com/ISMRM2021/PDFfiles/2007.html>.
65. Pouwels PJW, Frahm J. Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS. *NMR Biomed.* 1997;10(2). doi:10.1002/(SICI)1099-1492(199704)10:2<73::AID-NBM448>3.0.CO;2-4
66. Lin L, Považan M, Berrington A, Chen Z, Barker PB. Water removal in MR spectroscopic imaging with L2 regularization. *Magn Reson Med.* 2019;82(4):1278-1287. doi:10.1002/mrm.27824
67. Hangel G, Strasser B, Považan M, et al. A comparison of lipid suppression by double inversion recovery, L1- and L2-regularisation for high resolution MRSI in the brain at 7 T. In: *ISMRM 24th Annual Meeting & Exhibition.* ; 2016:2354.
68. Deelchand DK, Marjańska M, Hodges JS, Terpstra M. Sensitivity and specificity of human brain glutathione concentrations measured using short-TE 1 H MRS at 7 T. *NMR Biomed.* 2016;29(5):600-606. doi:10.1002/nbm.3507
69. Terpstra M, Ugurbil K, Tkac I. Noninvasive quantification of human brain ascorbate concentration using 1 H NMR spectroscopy at 7 T. *NMR Biomed.* 2010;23(3):227-232. doi:10.1002/nbm.1423
70. Simicic D, Rackayova V, Xin L, et al. In vivo macromolecule signals in rat brain 1H-MR spectra at 9.4T: Parametrization, spline baseline estimation, and T2 relaxation times. *Magn Reson Med.* 2021;(January):1-18. doi:10.1002/mrm.28910
71. Bhogal AA, Broeders TAA, Morsinkhof L, et al. Lipid-suppressed and tissue-fraction corrected metabolic distributions in human central brain structures using 2D 1H magnetic resonance spectroscopic imaging at 7 T. *Brain Behav.* 2020;10(12). doi:10.1002/brb3.1852
72. Jensen JE, de B. Frederick B, Renshaw PF. Grey and white matter GABA level differences in the human brain using two-dimensional, J-resolved spectroscopic imaging. *NMR Biomed.* 2005;18(8). doi:10.1002/nbm.994
73. Mullins PG, McGonigle DJ, O 'gorman RL, et al. Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA Cardiff Symposium on MRS of GABA and. *Neuroimage.* 2014;86.
74. Pouwels PJW, Brockmann K, Kruse B, et al. Regional age dependence of human brain metabolites from infancy to adulthood as detected by quantitative localized proton MRS.

- Pediatr Res.* 1999;46(4):474-485. doi:10.1203/00006450-199910000-00019
75. Srinivasan R, Ratiney H, Hammond-Rosenbluth KE, Pelletier D, Nelson SJ. MR spectroscopic imaging of glutathione in the white and gray matter at 7 T with an application to multiple sclerosis. *Magn Reson Imaging.* 2010;28(2). doi:10.1016/j.mri.2009.06.008
 76. Choi IY, Lee P. Doubly selective multiple quantum chemical shift imaging and T1 relaxation time measurement of glutathione (GSH) in the human brain in vivo. *NMR Biomed.* 2013;26(1). doi:10.1002/nbm.2815
 77. Andronesi OC, Nicholson K, Jafari-Khouzani K, et al. Imaging Neurochemistry and Brain Structure Tracks Clinical Decline and Mechanisms of ALS in Patients. *Front Neurol.* 2020;11. doi:10.3389/fneur.2020.590573
 78. Birch R, Peet AC, Dehghani H, Wilson M. Influence of macromolecule baseline on 1H MR spectroscopic imaging reproducibility. *Magn Reson Med.* 2017;77(1):34-43. doi:10.1002/mrm.26103
 79. Hnilicová P, Považan M, Strasser B, et al. Spatial variability and reproducibility of GABA-edited MEGA-LASER 3D-MRSI in the brain at 3 T. *NMR Biomed.* 2016;29(11):1656-1665. doi:10.1002/nbm.3613
 80. Penner J, Bartha R. Semi-LASER 1H MR spectroscopy at 7 Tesla in human brain: Metabolite quantification incorporating subject-specific macromolecule removal. *Magn Reson Med.* 2015;74(1):4-12. doi:10.1002/mrm.25380
 81. Snoussi K, Gillen JS, Horska A, et al. Comparison of brain gray and white matter macromolecule resonances at 3 and 7 Tesla. *Magn Reson Med.* 2015;74(3). doi:10.1002/mrm.25468
 82. Inglese M, Spindler M, Babb JS, Sunenshine P, Law M, Gonen O. Field, coil, and echo-time influence on sensitivity and reproducibility of brain proton MR spectroscopy. *Am J Neuroradiol.* 2006;27(3).
 83. Wijtenburg SA, Rowland LM, Oeltzschner G, Barker PB, Workman CI, Smith GS. Reproducibility of brain MRS in older healthy adults at 7T. *NMR Biomed.* 2019;32(2). doi:10.1002/nbm.4040
 84. Wijtenburg SA, Rowland LM, Edden RAE, Barker PB. Reproducibility of brain spectroscopy at 7T using conventional localization and spectral editing techniques. *J*

- Magn Reson Imaging*. 2013;38(2). doi:10.1002/jmri.23997
85. Terpstra M, Cheong I, Lyu T, et al. Test-retest reproducibility of neurochemical profiles with short-echo, single-voxel MR spectroscopy at 3T and 7T. *Magn Reson Med*. 2016;76(4). doi:10.1002/mrm.26022
 86. Hammen T, Stadlbauer A, Tomandl B, et al. Short TE single-voxel 1H-MR spectroscopy of hippocampal structures in healthy adults at 1.5 Tesla - How reproducible are the results? *NMR Biomed*. 2005;18(3). doi:10.1002/nbm.958
 87. Venkatraman TN, Hamer RM, Perkins DO, Song AW, Lieberman JA, Steen RG. Single-voxel 1H PRESS at 4.0T: Precision and variability of measurements in anterior cingulate and hippocampus. *NMR Biomed*. 2006;19(4). doi:10.1002/nbm.1055
 88. Saleh MG, Near J, Alhamud A, Robertson F, van der Kouwe AJW, Meintjes EM. Reproducibility of macromolecule suppressed GABA measurement using motion and shim navigated MEGA-SPECIAL with LCMoDel, jMRUI and GANNET. *Magn Reson Mater Physics, Biol Med*. 2016;29(6). doi:10.1007/s10334-016-0578-8
 89. Geurts JJG, Barkhof F, Castelijns JA, Uitdehaag BMJ, Polman CH, Pouwels PJW. Quantitative 1H-MRS of healthy human cortex, hippocampus, and thalamus: Metabolite concentrations, quantification precision, and reproducibility. *J Magn Reson Imaging*. 2004;20(3). doi:10.1002/jmri.20138
 90. Prinsen H, de Graaf RA, Mason GF, Pelletier D, Juchem C. Reproducibility measurement of glutathione, GABA, and glutamate: Towards in vivo neurochemical profiling of multiple sclerosis with MR spectroscopy at 7T. *J Magn Reson Imaging*. 2017;45(1). doi:10.1002/jmri.25356
 91. Bogner W, Otazo R, Henning A. Accelerated MR spectroscopic imaging - a review of current and emerging techniques. *NMR Biomed*. 2021;34(5). doi:10.1002/nbm.4314
 92. Juchem C, Cudalbu C, Graaf RA, et al. B 0 shimming for in vivo magnetic resonance spectroscopy: Experts' consensus recommendations. *NMR Biomed*. June 2020:e4350. doi:10.1002/nbm.4350

List of Figures and Tables

Table 1: Processing, post-processing and LCModel steps together with the quality metrics used for the different steps to optimize the procedure.

Table 2: Slice-wise intra-subject coefficient of variations (CVs, mean, std in %) for ten normalized concentration ratios (/tCr) for six configurations for all volunteers and either all slices (#) or slice 6-9 (*).

Figure 1: a) Anatomical image showing the slice positions of the 10 measured slices (total FOV 220 x 220 x 80 mm³) and the position of the three blocks of slices used for block wise B0 shimming. b) Sample spectra from a region with low and with high lipid contamination are shown from slice 5 and slice 7, respectively. The crosses indicate the origin of the sample spectra in the lipid maps of the non regularized data. Spectra without regularization (black line) and L2-regularization (black and blue line, respectively) are displayed. c) Anatomical images and respective lipid maps of each slice are shown for the data without regularization and with L2-regularization for volunteer V5.

Figure 2: Boxplots of the SNR of NAA (a) and Cr (b), FWHM of Cr (e) and the rms fit residual (f) are shown for all configurations without and with L2-regularization (nonreg vs L2), with and without simulated MM spectrum and with different LCModel baseline stiffness values (0.15, 0.25 and 1). Data from all measurements and volunteers are pooled. Corresponding slice specific values pooled across measurements and volunteers from the configurations “nonreg-MM-0.25” (red) and “L2-MM-0.25” (blue) are seen in c,d,g,h). In all boxplots, the horizontal line indicates the median and the boxes show the [25-, 75]-percentile interval.

Figure 3: CRLB (a) and voxels fitted (b) from LCModel for all configurations and different metabolites. Data from all measurements, volunteers and slices are pooled. CRLB and percentage of voxels fitted for the other metabolites can be found in the Supplementary Material Fig D.

Figure 4: Normalized concentration maps in arbitrary units for Glu/tCr (a), NAA/tCr (b), NAAG/tCr (c) for selected slices from volunteer V5 for all configurations. Be aware of the different color scale for NAAG due to better visibility of small concentrations. Both color scales are linear.

Figure 5: a) Sagittal and coronal metabolite ratio maps (/tCr) for four selected metabolites, underlayed with the anatomical images to illustrate the coverage of the cerebrum. b) Transversal metabolite ratio maps for all slices. Data from configuration L2-MM-0.25 and volunteer 5. Data reported in arbitrary units.

Figure 6: Metabolite ratio maps for volunteer V5 for both measurements to present the reproducibility of the measurement; configuration L2-MM-0.25 data. Data reported in arbitrary units. For four metabolites, only a subset of slices is shown due to unreliable results in lower slices.

Table 1: Processing, post-processing and LCModel steps together with the quality metrics used for the different steps to optimize the procedure.

Methods		Steps		
Reconstruction and Processing		<ol style="list-style-type: none"> 1. CS reconstruction of the accelerated water reference (wref) 2. Hanning filtering of the MRSI and wref data 3. spatial Fourier transformation of the MRSI and wref data 4. eddy current and phase correction of the MRSI and wref data using the wref data 5. coil combination using SVD of the MRSI and wref data 		
Post-Processing		<ol style="list-style-type: none"> 6. water removal using HSVD of the MRSI data 7. missing point prediction of the MRSI data 8. lipid regularization: 		
		No regularization		L2-regularization (same regularization parameter for all slices, derived from L-heuristic)
LCModel Fitting	Macro-Molecular spectra	Without macromolecule and lipid spectra	With simulated macromolecular spectrum	With simulated macromolecular spectrum
	LCModel stiffness parameter	0.15 (LCModel default) 0.25 1		
Configuration Name		nonreg-0.15 nonreg-0.25 nonreg-1	nonreg-MM-0.15 nonreg-MM-0.25 nonreg-MM-1	L2-MM-0.15 L2-MM-0.25 L2-MM-1
Quality Metrics		<ul style="list-style-type: none"> • SNR of NAA and Cr, FWHM • percentage of voxels with CRLB < 40 % for different metabolites • root-mean-square of the fit residual • Coefficient of variance for different metabolites • 2D/3D maps

Figure 1: a) Anatomical image showing the slice positions of the 10 measured slices (total FOV $220 \times 220 \times 80 \text{ mm}^3$) and the position of the three blocks of slices used for block wise B_0 shimming. b) Sample spectra from a region with low and with high lipid contamination are shown from slice 5 and slice 7, respectively. The crosses indicate the origin of the sample spectra in the lipid maps of the non regularized data. Spectra without regularization (black line) and L2-regularization (black and blue line, respectively) are displayed. c) Anatomical images and respective lipid maps of each slice are shown for the data without regularization and with L2-regularization for volunteer V5.

Figure 2: Boxplots of the SNR of NAA (a) and Cr (b), FWHM of Cr (e) and the rms fit residual (f) are shown for all configurations without and with L2-regularization (nonreg vs L2), with and without simulated MM spectrum and with different LCModel baseline stiffness values (0.15, 0.25 and 1). Data from all measurements and volunteers are pooled. Corresponding slice specific values pooled across measurements and volunteers from the configurations “nonreg-MM-0.25” (red) and “L2-MM-0.25” (blue) are seen in c,d,g,h). In all boxplots, the horizontal line indicates the median and the boxes show the [25-, 75]-percentile interval.

Figure 3: CRLB (a) and voxels fitted (b) from LCModel for all configurations and different metabolites. Data from all measurements, volunteers and slices are pooled. CRLB and percentage of voxels fitted for the other metabolites can be found in the Supplementary Material Fig D.

Figure 4: Normalized concentration maps in arbitrary units for Glu/tCr (a), NAA/tCr (b), NAAG/tCr (c) for selected slices from volunteer V5 for all configurations. Be aware of the different color scale for NAAG due to better visibility of small concentrations. Both color scales are linear.

Figure 5: a) Sagittal and coronal metabolite ratio maps (/tCr) for four selected metabolites, underlaid with the anatomical images to illustrate the coverage of the cerebrum. b) Transversal metabolite ratio maps for all slices. Data from configuration L2-MM-0.25 and volunteer 5. Data reported in arbitrary units.

Figure 6: Metabolite ratio maps for volunteer V5 for both measurements to present the reproducibility of the measurement; configuration L2-MM-0.25 data. Data reported in arbitrary units. For four metabolites, only a subset of slices is shown due to unreliable results in lower slices.

Metabolite (/tCr) vs. Method	NAA [#]		tCho [#]		Glu [#]		ml [#]		Asp [*]	
	mean	std	mean	std	mean	std	mean	std	mean	std
nonreg-0.15	5.6	3.3	5	3.2	7.4	4.2	7.2	2.9	14.0	8.6
nonreg-0.25	6.3	3.6	5.1	3.2	8.4	4.6	9.0	3.4	16.0	7.7
nonreg-1	10.8	5.9	12.6	16.4	14.3	8.9	20.0	8.2	23.3	11.5
nonreg-MM-0.15	6.2	3.3	4.6	2.7	6.5	4.2	7.4	2.9	15.4	5.0
nonreg-MM-0.25	6.3	3.6	5.1	3.4	8.3	5.2	12.8	1.1	15.8	7.0
nonreg-MM-1	9.1	5.4	12	14.1	14.4	10.8	29.1	13.4	25.3	18.0
L2-MM-0.15	7.2	4.9	4.3	2.3	11	7.1	12.6	8.7	15.0	0.8
L2-MM-0.25	8.5	4.7	4.1	2.2	10.3	6.2	16.7	8.8	17.3	5.5
L2-MM-1	8.9	4.5	5.4	2.5	14.1	9.2	23.3	8.0	26.3	9.2
Metabolite (/tCr) vs. Method	GABA [*]		Gln [*]		NAAG [*]		Tau [*]		GSH [*]	
	mean	std	mean	std	mean	std	mean	std	mean	std
nonreg-0.15	8.0	3.6	14.3	8.7	15.6	4.2	21.1	11.3	4.9	2.0
nonreg-0.25	9.2	4.3	15.9	9.0	16.5	3.6	24.4	10.3	4.2	2.4
nonreg-1	11.1	3.3	27.9	28.2	14.4	5.4	51.2	38.1	9.9	5.4
nonreg-MM-0.15	8.2	5.1	16.1	9.1	19.5	4.5	18.8	11.1	9.5	2.3
nonreg-MM-0.25	9.0	4.6	22.1	13.9	20.8	7.2	22.0	8.6	10.5	3.7
nonreg-MM-1	12.5	4.2	23.5	27.5	11.3	7.7	30.8	15.7	22.6	5.1
L2-MM-0.15	10.6	6.4	17.7	13.1	19.5	12.5	19.2	20.2	6.2	2.5
L2-MM-0.25	13.8	6.8	22.3	16.9	33.7	23	35.3	20.6	7.1	2.4
L2-MM-1	14.5	5.1	28.0	19.3	12.2	5.2	89.4	28.9	12.6	2.2

Table 2: Slice-wise intra-subject coefficient of variations (CVs, mean, std in %) for ten normalized concentration ratios (/tCr) for six configurations for all volunteers and either all slices ([#]) or slice 6-9 (^{*}).

List of Supporting Information

Supporting Information to the Method Section (Text)

Figure A: L-curve (lipid basis norm vs. L2 of consistency) and the corresponding curvature (b) from one sample slice. Curvatures from different slices and volunteers (c).

LCModel .control File:

Figure B: Sample spectra from dominant gray matter (a) and white matter (b) voxel with all fitted metabolites for the configuration L2-MM-0.25.

Figure C: Data, fit, MM spectrum, residual and spline baseline for each configuration from one sample spectrum of volunteer V5.

Figure D: CRLB (a) and voxels fitted (b) from LCModel for all configurations and different metabolites. Data from all measurements, volunteers and slices are pooled.

Figure E: Coefficient of variance of the metabolite ratios (/tCr) for the test-retest measurements for all configurations and ten metabolite concentration ratios. Data pooled from all volunteers and a) all slices, b) slice 6-9.

Figure F: mI/tCr concentration ratio maps for the configurations: nonreg-0.15, nonreg-0.25, nonreg-1 and nonreg-MM-0.15, nonreg-MM-0.25, nonreg-MM-1 for volunteer 5. Data reported in arbitrary units.

Figure G: Comparison of metabolite ratio maps (NAA/tCr and Glu/tCr) for different regularization parameters: First row shows non-regularized data, the rows below show L2-regularized data for $\beta=100, 1000, 5000, 10000$ and 106, respectively.

LCModel Basis Set